NY-ESO-1

NY-ESO-1 is a human tumor antigen of the cancer/testis family.[1]

It is highly expressed in many poor-prognosis melanomas.[2]

It is being studied as possible target for a cancer vaccine or immunotherapy.

It is a target for some experimental engineered T-cell therapies for myeloma.[3]

See also

References

  1. ↑ Gnjatic et al. (2006). "NY-ESO-1: review of an immunogenic tumor antigen.". Adv Cancer Res. 2006;95:1-30.
  2. ↑ NY-ESO-1 is highly expressed in poor-prognosis multiple myeloma and induces spontaneous humoral and cellular immune responses. Blood. 2005
  3. ↑ NY-ESO-1-specific TCR-engineered T cells mediate sustained antigen-specific antitumor effects in myeloma. Nat Med. 2015 Aug;21(8):914-21. doi:10.1038/nm.3910.

Further reading

This article is issued from Wikipedia - version of the Sunday, April 17, 2016. The text is available under the Creative Commons Attribution/Share Alike but additional terms may apply for the media files.